Research progress on nephrotoxicity and decorporation agents of depleted uranium

doi:10.3877/cma.j.issn.1673-9450.2024.01.016

Abstract

Abstract:

Depleted uranium is a by-product of uranium enrichment and processing into nuclear fuel, which has both radioactive and chemical toxicity. Once accidentally released into the environment, it enters the human body through the respiratory tract and digestive tract, and is easy to accumulate in the kidneys and other organs, seriously endangering human health. This paper reviews the research progress of depleted uranium nephrotoxicity and decorporation agents, in order to understand the research status of them, and to provide ideas for the further study of efficient uranium excretion enhancers.

Key words: Depleted uranium, Nephrotoxicity, Decorporation agents

Wenrun Li, Li Shen, Chang Shu, Suiyi Liu, Yonghong Ran, Xinze Ran, Yuhui Hao. Research progress on nephrotoxicity and decorporation agents of depleted uranium[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(01): 83-86.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2024.01.016

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2024/V19/I01/83

References 48

[1]	Yue YC, Li MH, Wang HB, et al. The toxicological mechanisms and detoxification of depleted uranium exposure[J]. Environ Health Prev Med, 2018, 23(1): 18.
[2]	Ma M, Wang R, Xu L, et al. Emerging health risks and underlying toxicological mechanisms of uranium contamination: lessons from the past two decades[J]. Environ Int, 2020, 145: 106107.
[3]	Carugo O. Structural features of uranium-protein complexes[J]. J Inorg Biochem, 2018, 189: 1-6.
[4]	Creff G, Zurita C, Jeanson A, et al. What do we know about actinides-proteins interactions？[J]. Radiochimica Acta, 2019, 107(9-11): 993-1009.
[5]	Shaki F, Zamani E, Arjmand A, et al. A review on toxicodynamics of depleted uranium[J]. Iran J Pharm Res, 2019, 18 Suppl 1: 90-100.
[6]	Asic A, Kurtovic-Kozaric A, Besic L, et al. Chemical toxicity and radioactivity of depleted uranium: the evidence from in vivo and in vitro studies[J]. Environ Res, 2017, 156: 665-673.
[7]	Schilz JR, Dashner-Titus EJ, Simmons KA, et al. The immunotoxicity of natural and depleted uranium: from cells to people[J]. Toxicol Appl Pharmacol, 2022, 454: 116252.
[8]	Cocco P. Cancer incidence among the NATO peacekeeping forces in Bosnia and Kosovo: a systematic review and metanalysis[J]. Med Lav, 2022, 113(1): e2022011.
[9]	Kitahara K, Numako C, Terada Y, et al. Uranium XAFS analysis of kidney from rats exposed to uranium[J]. J Synchrotron Radiat, 2017, 24(Pt 2): 456-462.
[10]	Cheng X, Chu J, Zhang L, et al. Intracellular and extracellular untargeted metabolomics reveal the effect of acute uranium exposure in HK-2 cells[J]. Toxicology, 2022, 473: 153196.
[11]	Yu L, Li W, Chu J, et al. Uranium inhibits mammalian mitochondrial cytochrome c oxidase and ATP synthase[J]. Environ Pollut, 2021, 271: 116377.
[12]	Wen Y, Vechetti IJ, Leng D, et al. Early transcriptomic signatures and biomarkers of renal damage due to prolonged exposure to embedded metal[J]. Cell Biol Toxicol, 2023, 39(6): 2861-2880.
[13]	Liu S, Wang S, Zhao Y, et al. Depleted uranium causes renal mitochondrial dysfunction through the ETHE1/Nrf2 pathway[J]. Chem Biol Interact, 2023, 372: 110356.
[14]	Hu Q, Zheng J, Xu XN, et al. Uranium induces kidney cells apoptosis via reactive oxygen species generation, endoplasmic reticulum stress and inhibition of PI3K/AKT/mTOR signaling in culture[J]. Environ Toxicol, 2022, 37(4): 899-909.
[15]	Hu Q, Zhang R, Zheng J, et al. Hydrogen sulfide attenuates uranium-induced kidney cells pyroptosis via upregulation of PI3K/AKT/mTOR signaling[J]. J Biochem Mol Toxicol, 2023, 37(1): e23220.
[16]	Yuan Y, Zheng J, Zhao T, et al. Uranium-induced rat kidney cell cytotoxicity is mediated by decreased endogenous hydrogen sulfide (H₂S) generation involved in reduced Nrf2 levels[J]. Toxicol Res (Camb), 2016, 5(2): 660-673.
[17]	Hao Y, Huang J, Ran Y, et al. Ethylmalonic encephalopathy 1 initiates overactive autophagy in depleted uranium-induced cytotoxicity in the human embryonic kidney 293 cells[J]. J Biochem Mol Toxicol, 2021, 35(3): e22669.
[18]	Fattal E, Tsapis N, Phan G. Novel drug delivery systems for actinides (uranium and plutonium) decontamination agents[J]. Advanced Drug Delivery Reviews, 2015, 90: 40-54.
[19]	Felipe-Sotelo M, Edgar M, Beattie T, et al. Effect of anthropogenic organic complexants on the solubility of Ni, Th, U(IV) and U(VI)[J]. J Hazard Mater, 2015, 300: 553-560.
[20]	Durbin PW. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators[J]. Health Phys, 2008, 95(5): 465-492.
[21]	Abergel RJ, Durbin PW, Kullgren B, et al. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3, 4, 3-LI(1, 2-HOPO) and 5-LIO(Me-3, 2-HOPO)[J]. Health Phys, 2010, 99(3): 401-417.
[22]	Bunin DI, Chang PY, Doppalapudi RS, et al. Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen[J]. Radiat Res, 2013, 179(2): 171-182.
[23]	Wang X, Dai X, Shi C, et al. A 3, 2-Hydroxypyridinone-based decorporation agent that removes uranium from bones in vivo[J]. Nat Commun, 2019, 10(1): 257.
[24]	Fukuda S, Ikeda M, Nakamura M, et al. Efficacy of oral and intraperitoneal administration of CBMIDA for removing uranium in rats after parenteral injections of depleted uranium[J]. Radiat Prot Dosimetry, 2009, 133(1): 12-19.
[25]	Bao Y, Wang D, Hu Y, et al. Efficacy of chelator CBMIDA-CaNa₂ for the removal of uranium and protection against uranium-induced cell damage in human renal proximal tubular cells[J]. Health Phys, 2013, 105(1): 31-38.
[26]	Bao Y, Wang D, Li Z, et al. Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells[J]. Toxicology and Applied Pharmacology, 2013, 269(1): 17-24.
[27]	Henge-Napoli MH, Ansoborlo E, Chazel V, et al. Efficacy of ethane-1-hydroxy-1, 1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats[J]. Int J Radiat Biol, 1999, 75(11): 1473-1477.
[28]	Bozal CB, Martinez AB, Cabrini RL, et al. Effect of ethane-1-hydroxy-1, 1-bisphosphonate (EHBP) on endochondral ossification lesions induced by a lethal oral dose of uranyl nitrate[J]. Arch Toxicol, 2005, 79(8): 475-481.
[29]	Ubios AM, Braun EM, Cabrini RL. Effect of biphosphonates on abnormal mandibular growth of rats intoxicated with uranium[J]. Health Phys, 1998, 75(6): 610-613.
[30]	Tymen H, Gerasimo P, Hoffschir D. Contamination and decontamination of rat and human skin with plutonium and uranium, studied with a Franz′s chamber[J]. Int J Radiat Biol, 2000, 76(10): 1417-1424.
[31]	Houpert P, Chazel V, Paquet F, et al. Reduction of uranium transfer by local chelation in simulated wounds in rats[J]. Hum Exp Toxicol, 2001, 20(5): 237-241.
[32]	Houpert P, Chazel V, Paquet F. A local approach to reduce industrial uranium wound contamination in rats[J]. Can J Physiol Pharmacol, 2004, 82(2): 73-78.
[33]	Cebrian D, Tapia A, Real A, et al. Inositol hexaphosphate: a potential chelating agent for uranium[J]. Radiat Prot Dosimetry, 2007, 127(1-4): 477-479.
[34]	Dinse C, Baglan N, Cossonnet C, et al. New purification protocol for actinide measurement in excreta based on calixarene chemistry[J]. Appl Radiat Isot, 2000, 53(1-2): 381-386.
[35]	Phan G, Semili N, Bouvier-Capely C, et al. Calixarene cleansing formulation for uranium skin contamination[J]. Health Phys, 2013, 105(4): 382-389.
[36]	Belhomme-Henry C, Phan G, Huang N, et al. Texturing formulations for uranium skin decontamination[J]. Pharm Dev Technol, 2014, 19(6): 692-701.
[37]	Michailidou G, Koumentakou I, Liakos EV, et al. Adsorption of uranium, mercury, and rare earth elements from aqeous solutions onto magnetic chitosan adsorbents: a review[J]. Polymers (Basel), 2021, 13(18): 3137.
[38]	Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner[J]. Nat Nanotechnol, 2012, 7(6): 383-388.
[39]	Li Z, Wang S, Dong Y, et al. Amidoxime functionalized chitosan for uranium sequestration in vivo[J]. Ecotoxicol Environ Saf, 2022, 239: 113636.
[40]	Mousavi SZ, Nafisi S, Maibach HI. Fullerene nanoparticle in dermatological and cosmetic applications[J]. Nanomedicine, 2017, 13(3): 1071-1087.
[41]	Liu XQ, Yang YY, Liao JL, et al. Efficient removal of uranium from mice by a novel compound of fullerence multi-macrocyclic polyamine derivatives[J]. Nuclear Science and Techniques, 2015, 26(4).
[42]	Zheng T, Wan X, Zhang Q, et al. Catechol amide derivatized polyhydroxylated fullerene as potential chelating agents of radionuclides: synthesis, reactive oxygen species scavenging, and cytotoxic studies[J]. J Inorg Biochem, 2020, 203: 110921.
[43]	Li J, Wang X, Zhao G, et al. Metal-organic framework-based materials: superior adsorbents for the capture of toxic and radioactive metal ions[J]. Chem Soc Rev, 2018, 47(7): 2322-2356.
[44]	de Koning MC, Vieira Soares C, van Grol M, et al. Effective degradation of novichok nerve agents by the zirconium metal-organic framework MOF-808[J]. ACS Appl Mater Interfaces, 2022, 14(7): 9222-9230.
[45]	Wang X, Chen L, Bai Z, et al. In vivo uranium sequestration using a nanoscale metal-organic framework[J]. Angew Chem Int Ed Engl, 2021, 60(3): 1646-1650.
[46]	Chen L, Wang X, Chen M, et al. Self-aggregated nanoscale metal-organic framework for targeted pulmonary decorporation of Uranium[J]. Adv Healthc Mater, 2023: e2300510.
[47]	Shi C, Wang X, Wan J, et al. 3, 2-Hydroxypyridinone-grafted chitosan oligosaccharide nanoparticles as efficient decorporation agents for simultaneous removal of uranium and radiation-induced reactive oxygen species in vivo[J]. Bioconjug Chem, 2018, 29(11): 3896-3905.
[48]	Shi P, Wang X, Zhang H, et al. Boosting simultaneous uranium decorporation and reactive oxygen species scavenging efficiency by lacunary polyoxometalates[J]. ACS Appl Mater Interfaces, 2022, 14(49): 54423-54430.

Please choose a citation manager

Content to export